Ewida Heba A, Shabayek Marwa, Seleem Mae
Department of Pharmacology and Biochemistry, Faculty of Pharmaceutical Sciences & Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt.
Breast Dis. 2021;40(4):241-250. doi: 10.3233/BD-201076.
Molecular markers for the detection of breast cancer and its different types, grades, and stages lack enough sensitivity and specificity. This study evaluates the expression of miRNAs 9 and 342 in sera of different types, grades, and stages of BC. Moreover, the assessment of their sensitivity, specificity, diagnostic, and prognostic role in detecting different types of BC.
Blood was collected from 200 females outpatients, divided into five groups each 40 subjects: control, benign breast tumor, estrogen receptor (ER+)/progesterone receptor (PR+) BC, human epidermal growth factor receptor (HER+) BC, and triple-negative BC. BC subjects were further subdivided according to grade and stage. Expressions of miRNAs 9 and 342 were measured for all subjects by real-time polymerase chain reaction (RT-PCR).
Results showed that serum expression of both miRNAs 9 and 342 can be used for the diagnosis of different types of BC. Their expression can be used to significantly differentiate between different grades and stages of BC. MiRNAs 9 and 342 showed high sensitivity of 92.5% and specificity of (81.2 and 88.7%), respectively, for triple-negative BC.
The expressions of miRNAs 9 and 342 provide potential roles as serological biomarkers for the diagnosis and prognosis of different types, grades, and stages of BC.
用于检测乳腺癌及其不同类型、分级和分期的分子标志物缺乏足够的敏感性和特异性。本研究评估了miRNAs 9和342在不同类型、分级和分期的乳腺癌患者血清中的表达情况。此外，还评估了它们在检测不同类型乳腺癌中的敏感性、特异性、诊断和预后作用。
收集了200名女性门诊患者的血液，分为五组，每组40名受试者：对照组、乳腺良性肿瘤组、雌激素受体（ER+）/孕激素受体（PR+）乳腺癌组、人表皮生长因子受体（HER+）乳腺癌组和三阴性乳腺癌组。乳腺癌患者根据分级和分期进一步细分。通过实时聚合酶链反应（RT-PCR）检测所有受试者中miRNAs 9和342的表达。
结果表明，miRNAs 9和342的血清表达均可用于诊断不同类型的乳腺癌。它们的表达可用于显著区分乳腺癌的不同分级和分期。对于三阴性乳腺癌，miRNAs 9和342分别显示出92.5%的高敏感性和（81.2%和88.7%）的特异性。
miRNAs 9和342的表达作为血清生物标志物在不同类型、分级和分期乳腺癌的诊断和预后中具有潜在作用。
